Willems E, Gerne L, George C, D'Hondt M
Department of Digestive and Hepatobiliary/Pancreatic Surgery, AZ Groeninge Kortrijk, Belgium.
Department of Gastro-enterology, AZ Groeninge Kortrijk, Belgium.
Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):322-325.
Colorectal cancer is one of the most frequently diagnosed malignancies worldwide. One of the most important developments in the management of metastatic colorectal cancer is targeted therapy. Bevacizumab, a monoclonal antibody inhibiting VEGF induced angiogenesis, has been accepted as safe and efficient in the treatment of metastatic colorectal cancer for more than a decade. Addition of bevacizumab to fluorouracil-based chemotherapy is also associated with severe adverse events. We present a case of bevacizumab-induced bowel ischaemia associated with gastrointestinal haemorrhage.
结直肠癌是全球最常被诊断出的恶性肿瘤之一。转移性结直肠癌治疗中最重要的进展之一是靶向治疗。贝伐单抗是一种抑制血管内皮生长因子（VEGF）诱导血管生成的单克隆抗体，十多年来一直被认为在转移性结直肠癌治疗中安全有效。在基于氟尿嘧啶的化疗中添加贝伐单抗也会引发严重不良事件。我们报告一例与胃肠道出血相关的贝伐单抗诱发的肠道缺血病例。
